Poland
· Delayed Price · Currency is PLN InventionMed Statistics
Total Valuation
InventionMed has a market cap or net worth of PLN 41.77 million. The enterprise value is 41.77 million.
| Market Cap | 41.77M |
| Enterprise Value | 41.77M |
Important Dates
The next estimated earnings date is Friday, February 14, 2025.
| Earnings Date | Feb 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
InventionMed has 202.79 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 202.79M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.61% |
| Owned by Institutions (%) | n/a |
| Float | 113.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 257.50 |
| PB Ratio | 14.62 |
| P/TBV Ratio | 15.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.20 |
| EV / Sales | 257.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.89 |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.59 |
Financial Efficiency
Return on equity (ROE) is -94.27% and return on invested capital (ROIC) is -36.16%.
| Return on Equity (ROE) | -94.27% |
| Return on Assets (ROA) | -5.25% |
| Return on Invested Capital (ROIC) | -36.16% |
| Return on Capital Employed (ROCE) | -13.70% |
| Revenue Per Employee | 40,580 |
| Profits Per Employee | -1.27M |
| Employee Count | 7 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.24% in the last 52 weeks. The beta is 0.38, so InventionMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -13.24% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.21 |
| Relative Strength Index (RSI) | 51.54 |
| Average Volume (20 Days) | 251,157 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InventionMed had revenue of PLN 162,320 and -5.09 million in losses. Loss per share was -0.03.
| Revenue | 162,320 |
| Gross Profit | 15,770 |
| Operating Income | -3.13M |
| Pretax Income | -5.09M |
| Net Income | -5.09M |
| EBITDA | -1.44M |
| EBIT | -3.13M |
| Loss Per Share | -0.03 |
Balance Sheet
| Cash & Cash Equivalents | 4,692 |
| Total Debt | n/a |
| Net Cash | 4,692 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 2.86M |
| Book Value Per Share | 0.01 |
| Working Capital | -15.21M |
Cash Flow
In the last 12 months, operating cash flow was 441,317 and capital expenditures -4.28 million, giving a free cash flow of -3.83 million.
| Operating Cash Flow | 441,317 |
| Capital Expenditures | -4.28M |
| Free Cash Flow | -3.83M |
| FCF Per Share | -0.02 |
Margins
| Gross Margin | 9.72% |
| Operating Margin | -1,925.87% |
| Pretax Margin | -3,138.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
InventionMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -12.20% |
| FCF Yield | -9.18% |
Stock Splits
The last stock split was on September 6, 2022. It was a forward split with a ratio of 4.
| Last Split Date | Sep 6, 2022 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
InventionMed has an Altman Z-Score of -1.12. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.12 |
| Piotroski F-Score | n/a |